NOVARTIS AG
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
As a % of sales 20.7 14.7 20.9 19.2
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Core operating income 3 501 3 462 1 2 15 416 14 112 9 13
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
As a % of sales 27.4 27.9 31.7 29.7
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Net income 2 099 1 129 86 93 8 071 7 147 13 20
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
EPS (USD) 0.92 0.50 84 93 3.55 3.12 14 21
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Core net income 3 034 2 985 2 3 13 158 12 104 9 12
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Core EPS (USD) 1.34 1.32 2 3 5.78 5.28 9 13
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Cash flows from
operating activities 4 005 3 540 13 13 650 13 547 1
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Free cash flow 3 342 3 488 -4 11 691 12 937 -10
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Q4 Q4 FY FY
Innovative Medicines 2020 2019 % change 2020 2019 % change
USD m USD m USD cc USD m USD m USD cc
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Net sales 10 233 9 920 3 1 39 013 37 714 3 4
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Operating income 2 386 2 210 8 12 9 172 9 287 -1 4
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
As a % of sales 23.3 22.3 23.5 24.6
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Core operating income 3 212 3 122 3 3 13 645 12 650 8 11
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
As a % of sales 31.4 31.5 35.0 33.5
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Q4 Q4 FY FY
Sandoz 2020 2019 % change 2020 2019 % change
USD m USD m USD cc USD m USD m USD cc
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Net sales 2 537 2 483 2 0 9 646 9 731 -1 0
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Operating income 372 -195 nm nm 1 043 551 89 106
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
As a % of sales 14.7 -7.9 10.8 5.7
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Core operating income 528 517 2 3 2 334 2 094 11 15
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
As a % of sales 20.8 20.8 24.2 21.5
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Q4 Q4 FY FY
Corporate 2020 2019 % change 2020 2019 % change
USD m USD m USD cc USD m USD m USD cc
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Operating loss -114 -192 41 45 -63 -752 nm nm
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Core operating loss -239 -177 -35 -28 -563 -632 11 14
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Q4 Q4 FY FY
Discontinued operations 2020 2019 % change 2020 2019 % change
USD m USD m USD cc USD m USD m USD cc
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Net sales 1 777
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Operating income 71
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
As a % of sales 4.0
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Core operating income 350
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
As a % of sales 19.7
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Net Income 4 590
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Q4 Q4 FY FY
Total Group 2020 2019 % change 2020 2019 % change
USD m USD m USD cc USD m USD m USD cc
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Net income 2 099 1 129 86 93 8 071 11 737 -31 -27
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
EPS (USD) 0.92 0.50 84 93 3.55 5.12 -31 -26
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Core net income 3 034 2 985 2 3 13 158 12 382 6 9
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Core EPS (USD) 1.34 1.32 2 3 5.78 5.40 7 10
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Cash flows
from operating activities 4 005 3 540 13 13 650 13 625 0
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
Free cash flow 3 342 3 488 -4 11 691 12 875 -9
--------------------------- ------ ------ ----- ----- ------ ------ ---- ------
nm = not meaningful
(1) Continuing operations include the businesses of Innovative Medicines
and Sandoz Division as well as the continuing corporate functions and
discontinued operations include the business of Alcon. See page 43 of
the Condensed Financial Report for full explanation.
(2) Constant currencies (cc), core results and free cash flow are
non-IFRS measures. An explanation of non-IFRS measures can be found on
page 55 of the Condensed Financial Report. Unless otherwise noted, all
growth rates in this Release refer to same period in prior year.
Detailed financial results accompanying this press release are included
in the Condensed Financial Report at the link below:
https://ml-eu.globenewswire.com/resource/download/62b8c900-3637-4459-a7a1-da6012d415b5/
Disclaimer
This press release contains forward-looking statements within the
meaning of the United States Private Securities Litigation Reform Act of
1995, that can generally be identified by words such as "next wave,"
"transformative," "continuing," "progressing," "guidance," "will result,
" "looking ahead," "confident," "progress," "to execute," "continue,"
"expect," "remains," "to maintain," "continues," "to evolve," "to take,"
"to help," "remain," "remains," "to grow," "continues," "to evolve,"
"continue," "to help," "remain," "to meet," "ongoing," "allowing,"
"launch," "addresses," "to work," "undertaking," "to develop,"
"investigating," "growing," "growth," "to support," "expected," "to be,"
"assume," "would," "estimates," "to advance," "to solidify," "committed,
" "enabling" "to progress," "allowing," "anticipate," "pipelines," "to
supplement," "investigational," "taking," "will," "estimated," "impact,"
"submissions," "focus," "launches," "innovation," "potential," "pipeline,
" "priority," "outlook," "unforeseen," "forecast," "prevail," "enter,"
"to improve," "transformative," "manageable disruptions," "ongoing
disruptions," "to delay," or similar expressions, or by express or
implied discussions regarding potential new products, potential new
indications for existing products, potential product launches, or
regarding potential future revenues from any such products; or regarding
the impact of the COVID-19 pandemic on certain therapeutic areas
including dermatology, ophthalmology and the Sandoz retail business, and
on drug development operations; or regarding potential future, pending
or announced transactions; regarding potential future sales or earnings
of the Group or any of its divisions; or by discussions of strategy,
plans, expectations or intentions; or regarding the Group's liquidity or (MORE TO FOLLOW) Dow Jones Newswires
January 26, 2021 01:00 ET (06:00 GMT)
